前立腺癌とHLAに関する研究
スポンサーリンク
概要
- 論文の詳細を見る
前立腺癌患者53例を対象としてHLA-A, BおよびDR抗原分析をおこなった.1)前立腺癌患者においてHLA-A, BおよびDRに高頻度に発現する特異抗原は認められなかった.2) HLA-A11およびHLA-B5の発現頻度が正常対照に比し前立腺癌患者において有意に低値を示した.3)前立腺癌患者stage D症例にHLA-A11を認めなかった.4)死亡症例11例にHLA-A11, HLA-B5を持つ症例は少なくHLA-A11, HLA-B5両抗原を同時に持つ者は1例のみであったA comparative study of HLA-A and HLA-B antigens frequency was made on 53 patients with histologically proved carcinoma of prostate. The patients were compared with 70 healthy controls. HLA-DR antigens were investigated in 23 patients. Typing was done by Terasaki's microdroplet lymphocyte cytotoxicity test. No significant increase of HLA-A, B or DR antigen associated with carcinoma of prostate could be demonstrated. HLA-A11 and HLA-B5 were associated with this disease less frequently. No HLA-A11 antigen was detected in stage D cases. Among 11 deaths, both HLA-A11 and HLA-B5 were found in only one case.
- 泌尿器科紀要刊行会の論文